Cargando…

Cost-effectiveness of PARP inhibitors in malignancies: A systematic review

OBJECTIVES: Poly (ADP-ribose) polymerase inhibitor (PARPi) have become a mainstay for the treatment of BRCA-mutant malignancies. PARPis are likely to be more effective but also bring an increase in costs. Thus, we aimed at evaluating the cost effectiveness of PARPis in the treatment of malignancies....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Haiying, He, Chaoneng, Tong, Yinghui, Fang, Qilu, Mi, Xiufang, Chen, Lingya, Xin, Wenxiu, Fang, Luo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754183/ https://www.ncbi.nlm.nih.gov/pubmed/36520958 http://dx.doi.org/10.1371/journal.pone.0279286

Ejemplares similares

Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial
por: Xin, Wenxiu, et al.
Publicado: (2020)

Pharmacist-led standardization of total parenteral nutrition improves postoperative nutritional status in colorectal cancer patients
por: Tong, Yinghui, et al.
Publicado: (2022)

Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
por: Ding, Haiying, et al.
Publicado: (2020)

Modified microvessel density based on perfusion distance: a preferable NSCLC prognostic factor
por: Tong, Yinghui, et al.
Publicado: (2022)

Caffeic acid phenethyl ester suppresses metastasis of breast cancer cells by inactivating FGFR1 via MD2
por: Fang, Qilu, et al.
Publicado: (2023)

Methadone switching for refractory cancer pain
por: Ding, Haiying, et al.
Publicado: (2022)

Reply to “A better interpretation of data regarding the opioid switching to methadone”
por: Ding, Haiying, et al.
Publicado: (2023)

Identification and validation of the microRNAs and hub genes for pancreatic ductal adenocarcinoma by an integrated bioinformatic analysis
por: Xin, Wenxiu, et al.
Publicado: (2023)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
por: Reinbolt, Raquel E., et al.
Publicado: (2013)

PARP Inhibitors and Haematological Malignancies—Friend or Foe?
por: Skelding, Kathryn A., et al.
Publicado: (2021)

Long Distance From Microvessel to Cancer Cell Predicts Poor Prognosis in Non-Small Cell Lung Cancer Patients
por: Ding, Haiying, et al.
Publicado: (2021)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

Spectrum-Effect Relationship-Based Strategy Combined with Molecular Docking to Explore Bioactive Flavonoids from Sceptridium ternatum
por: Zhu, Junfeng, et al.
Publicado: (2022)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

A two-step mechanism governing PARP1-DNA retention by PARP inhibitors
por: Xue, Huijun, et al.
Publicado: (2022)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Flattened microvessel independently predicts poor prognosis of patients with non-small cell lung cancer
por: Fang, Luo, et al.
Publicado: (2017)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Dual Inhibitors of PARPs and ROCKs
por: Antolín, Albert A., et al.
Publicado: (2018)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

Virtual screening for plant PARP inhibitors – what can be learned from human PARP inhibitors?
por: Heym, Peter-Paul, et al.
Publicado: (2012)

Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review)
por: Rivero Belenchón, Inés, et al.
Publicado: (2023)

PARP inhibitors combined with radiotherapy: are we ready?
por: Sun, Chen, et al.
Publicado: (2023)

PARP Inhibitors in Ovarian Cancer: A Review
por: O’Malley, David M., et al.
Publicado: (2023)

A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma
por: Li, Hui, et al.
Publicado: (2022)

Serine-linked PARP1 auto-modification controls PARP inhibitor response
por: Prokhorova, Evgeniia, et al.
Publicado: (2021)

Targeting dePARylation selectively suppresses DNA repair–defective and PARP inhibitor–resistant malignancies
por: Chen, Shih-Hsun, et al.
Publicado: (2019)

The efficacy and adverse effects of PARP inhibitor combined with chemotherapy compared with chemotherapy alone in the treatment of cancer patient: A protocol for systematic review
por: Zhao, Suyue, et al.
Publicado: (2020)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Predicting PARP inhibitor sensitivity and resistance
por: Bebb, D. Gwyn, et al.
Publicado: (2012)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

In vitro analysis of PARP inhibitor nanoformulations
por: Baldwin, Paige, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ptk3954g4412nfgjccu0po48bt